Lista de obras -

A Phase II Study of Systemic Chemotherapy with Docetaxel, Cisplatin, and S-1 (DCS) Followed by Surgery in Gastric Cancer Patients with Extensive Lymph Node Metastasis: Japan Clinical Oncology Group Study JCOG1002 ⬇️

artículo científico publicado el 23 de abril de 2012

A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy ⬇️

artículo científico publicado el 17 de noviembre de 2011

A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab ⬇️

artículo científico publicado el 12 de mayo de 2011

A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer ⬇️

artículo científico publicado el 8 de febrero de 2012

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study

scientific article published on 06 March 2019

A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.

artículo científico publicado en 2016

A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma.

artículo científico publicado en 2017

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

artículo científico publicado en 2015

Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer

artículo científico publicado en 2017

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer ⬇️

artículo científico publicado el 1 de marzo de 2011

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer

artículo científico publicado en 2017

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival

artículo científico publicado en 2020

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.

artículo científico publicado en 2018

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

artículo científico publicado en 2018

Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer ⬇️

artículo científico publicado el 11 de agosto de 2011

Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

scientific article published on 01 May 2019

Correction to: Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center

artículo científico publicado en 2018

Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer ⬇️

artículo científico

Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.

artículo científico publicado en 2014

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.

artículo científico publicado en 2018

Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy

artículo científico publicado el 1 de enero de 2010

Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.

artículo científico publicado en 2017

Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.

artículo científico publicado en 2017

Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.

artículo científico publicado en 2018

Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer ⬇️

artículo científico publicado el 1 de septiembre de 2010

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

scientific article published on 03 July 2019

Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer

artículo científico publicado en 2010

Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study

artículo científico publicado en 2009

Improvement of Oral Intake following Chemotherapy in Gastric Cancer Patients with an Inability to Eat ⬇️

artículo científico publicado el 1 de enero de 2010

Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002)

artículo científico publicado en 2019

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research

artículo científico publicado en 2020

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake

artículo científico publicado en 2018

Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer

scientific article published on 17 May 2019

Myelomatous ascites: An unusual presenting sign of multiple myeloma ⬇️

artículo científico publicado el 10 de noviembre de 2001

Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma

scientific article published on 09 December 2019

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma ⬇️

artículo científico publicado el 16 de febrero de 2011

Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer

artículo científico publicado en 2019

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

artículo científico publicado en 2013

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer ⬇️

artículo científico publicado el 19 de agosto de 2011

Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer

artículo científico publicado en 2018

Prognostic Impact of the 6th and 7th American Joint Committee on Cancer TNM Staging Systems on Esophageal Cancer Patients Treated With Chemoradiotherapy ⬇️

artículo científico publicado el 28 de febrero de 2011

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

scientific article published on 01 February 2019

Recovery from Choriocarcinoma Syndrome Associated with a Metastatic Extragonadal Germ Cell Tumor Hemorrhage

artículo científico publicado en 2016

Recursive Partitioning Analysis for New Classification of Patients With Esophageal Cancer Treated by Chemoradiotherapy ⬇️

artículo científico publicado el 11 de marzo de 2012

Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer ⬇️

artículo científico publicado el 26 de marzo de 2011

Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis

artículo científico publicado en 2017

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.

artículo científico publicado en 2017

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT stud

artículo científico publicado en 2017

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study

artículo científico publicado en 2019

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

artículo científico publicado en 2019

Second-line chemotherapy for patients with advanced gastric cancer.

artículo científico publicado en 2017

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer ⬇️

artículo científico publicado el 5 de septiembre de 2010

Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain ⬇️

artículo científico publicado el 1 de junio de 2013

Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study

scientific article published on 31 May 2019

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer

scientific article published on 01 November 2018

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab

artículo científico publicado en 2018

Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

artículo científico publicado en 2020

Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials.

artículo científico publicado en 2017

[Chemotherapy for patients with advanced gastric cancer]

artículo científico publicado en 2018

Lista de obras de

A Phase II Study of Systemic Chemotherapy with Docetaxel, Cisplatin, and S-1 (DCS) Followed by Surgery in Gastric Cancer Patients with Extensive Lymph Node Metastasis: Japan Clinical Oncology Group Study JCOG1002 ⬇️

A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy ⬇️

A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab ⬇️

A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer ⬇️

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study

A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.

A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma.

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer ⬇️

Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer ⬇️

Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

Correction to: Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center

Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer ⬇️

Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.

Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy

Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.

Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.

Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.

Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer ⬇️

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer

Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study

Improvement of Oral Intake following Chemotherapy in Gastric Cancer Patients with an Inability to Eat ⬇️

Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002)

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake

Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer

Myelomatous ascites: An unusual presenting sign of multiple myeloma ⬇️

Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma ⬇️

Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer ⬇️

Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer

Prognostic Impact of the 6th and 7th American Joint Committee on Cancer TNM Staging Systems on Esophageal Cancer Patients Treated With Chemoradiotherapy ⬇️

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Recovery from Choriocarcinoma Syndrome Associated with a Metastatic Extragonadal Germ Cell Tumor Hemorrhage

Recursive Partitioning Analysis for New Classification of Patients With Esophageal Cancer Treated by Chemoradiotherapy ⬇️

Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer ⬇️

Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT stud

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

Second-line chemotherapy for patients with advanced gastric cancer.

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer ⬇️

Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain ⬇️

Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab

Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials.

[Chemotherapy for patients with advanced gastric cancer]